Jinpeng Jonathan Foo

Current ongoing research projects:

In vitro pharmacodynamics of apramycin, omadacycline and other novel antibiotics against a panel of multi-drug resistant gram negative isolates (Mar 24 - present)

• Analysed and evaluated a panel of novel antibiotics against a collection of multi-drug resistant gram negative isolates using antimicrobial susceptibility testing methods as well as whole genome sequencing.
• Main author of the manuscript, pending publication.
• This research was supported by the Singapore Ministry of Health’s National Medical Research Council (NMRC) under its NMRC Clinician Scientist Award (MOH-000276), NMRC Clinician Scientist Individual Research Grant (CIRG18Nov-0034), NMRC Collaborative Grant: Collaborative Solutions Targeting Antimicrobial Resistance Threats in Health Systems (CoSTAR-HS; CG21APR2005) and NMRC Open Fund – Large Collaborative Grant: AntiMicrobial resistance Research & Intervention Alliance Singapore (AMRITAS; MOH-001326-01).

Evaluating the use of cefoxitin non-susceptibility as a predictive marker for plasmid ampC Klebsiella pneumoniae and Escherichia Coli isolates (Aug 24 - present)

• Analyzed data from a previously done retrospective cohort study to evaluate the role of cefoxitin non-susceptibility as a possible predictive marker for plasmid ampC detection.
• Investigating the role of regulatory genes in the mediating plasmid AmpC resistance.
• Involved in manuscript writing, pending publication
• The study was funded under the RIE2020 Collaborative Centre Grant Seed Funding Program.

Past Research Projects:

Final Year Project (in partnership with Singapore General Hospital): In vitro pharmacodynamics of Ceftazidime-Avibactam in combination with other antimicrobials against carbapenem-resistant Enterobacterales (Dec 21 - Apr 22)
• Conducted time-kill studies on different resistant bacteria isolates to elucidate the best antibiotic combination regimen in vitro as part of my final year project.
• Familiarised myself with microbiology and aseptic techniques while handling highly resistant bacteria organisms.
• Acquainted with the In Vitro Antibiotic Combination Testing Service (iACT) at SGH which was a clinical service provided by infectious disease pharmacists to test antibiotic combinations for patients with multi-drug resistant organisms.

Acute Care/Inpatient pharmacist:

• Provides medication reconciliation and personalized bedside dispensing services.
• Assists with drug-related enquiries by other healthcare providers
• Optimize the safe and effective use of medications for inflight patients

Ambulatory Care/Clinic pharmacist:

• Offers specialized counseling to patients on antiretroviral therapies to enhance adherence and minimize treatment failure
• Advises and supports physicians on drug-related inquiries, including optimal selection of antiretroviral therapies and strategies to mitigate medication side effects

Education and Training

• Pharmacy Technician training overall-in-charge
• Pharmacist and Pharmacy Technician Continuing Education overall-in-charge
• Preceptor to NUS university students
• Pre-registration pharmacists dermatology/dengue clinical discussion instructor
• Nurses antimicrobial stewardship course teaching instructor

Operational

• NCID Pharmacy IT Lead
• Controlled Drugs Pharmacist in-charge

Outreach

• World AIDS Day Organising Committee Member

• Spearheaded a project regarding the Human Biomedical Research Act and was actively involved in proposing strategies to expedite the localization of informed consent documents while complying with new regulatory requirements
• Drafted regulatory submissions to Singhealth and National Healthcare Group (NHG) Institutional Review Board for ethics review
• Participated in clinical monitoring, site initiation and termination activities at different hospitals in Singapore
• Supported in the SOP review of investigational medicinal products by ensuring compliance to local regulatory standards
• Assisted in document reconciliation by using Novartis in-house clinical trial studies database
• Supported pharmacovigilance operations and assisted in the screening of adverse events for reporting to local health authorities
• Facilitated safety report submissions to Health Sciences Authorities (HSA) via the online Pharmaceutical Regulatory Information System (PRISM)